These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9694743)

  • 1. A novel factor V null mutation detected in a thrombophilic patient with pseudo-homozygous APC resistance and in an asymptomatic unrelated subject.
    Lunghi B; Castoldi E; Mingozzi F; Bernardi F; Castaman G
    Blood; 1998 Aug; 92(4):1463-4. PubMed ID: 9694743
    [No Abstract]   [Full Text] [Related]  

  • 2. Factor V Leiden (R506Q) and risk of venous thromboembolism: a case-control study based on the Spanish population.
    García-Gala JM; Alvarez V; Pinto CR; Soto I; Urgellés MF; Menéndez MJ; Carracedo C; López-Larrea C; Coto E
    Clin Genet; 1997 Oct; 52(4):206-10. PubMed ID: 9383024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [APC resistance--most frequent familial thrombophilia].
    Herren S; Lämmle B
    Ther Umsch; 1999 Sep; 56(9):499-501. PubMed ID: 10517118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The factor V Glu1608Lys mutation is recurrent in familial thrombophilia.
    Lunghi B; Scanavini D; Castoldi E; Gemmati D; Tognazzo S; Redaelli R; Ghirarduzzi A; Ieran M; Pinotti M; Bernardi F
    J Thromb Haemost; 2005 Sep; 3(9):2032-8. PubMed ID: 15975136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venous thrombosis: factor V G1691A genotyping related to APC resistance as measured by 2 methods.
    Alderborn A; Siegbahn A; Wadelius C
    Eur J Haematol; 1997 Apr; 58(4):229-32. PubMed ID: 9186532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel factor V mutation causes a normal activated protein C ratio despite the presence of a heterozygous F5 R506Q (factor V Leiden) mutation.
    Prüller F; Raggam RB; Mangge H; Truschnig-Wilders M; Matzhold EM; Weiss EC; Hasiba B; Summers KL; Renner W; Siegert G; Kostka H
    Br J Haematol; 2013 Nov; 163(3):414-7. PubMed ID: 23957718
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance.
    Guasch JF; Lensen RP; Bertina RM
    Thromb Haemost; 1997 Feb; 77(2):252-7. PubMed ID: 9157576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis.
    Zöller B; Dahlbäck B
    Lancet; 1994 Jun; 343(8912):1536-8. PubMed ID: 7911873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to activated protein C due to factor V R506Q mutation as a cause of venous thrombosis.
    Dahlbäck B
    Rev Invest Clin; 1997 May; 49 Suppl 1():3-5. PubMed ID: 9291738
    [No Abstract]   [Full Text] [Related]  

  • 10. Mutation in blood coagulation factor V associated with resistance to activated protein C.
    Bertina RM; Koeleman BP; Koster T; Rosendaal FR; Dirven RJ; de Ronde H; van der Velden PA; Reitsma PH
    Nature; 1994 May; 369(6475):64-7. PubMed ID: 8164741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double heterozygosity for Factor V Leiden and Factor V Cambridge mutations associated with low levels of activated protein C resistance in a Spanish thrombophilic family.
    Santamaría A; Soria JM; Tirado I; Mateo J; Coll I; Souto JC; Fontcuberta J
    Thromb Haemost; 2005 Jun; 93(6):1193-5. PubMed ID: 15968408
    [No Abstract]   [Full Text] [Related]  

  • 12. Ala147Thr and C+1542G polymorphisms in the TAFI gene are not asssociated with a higher risk of venous thrombosis in FV Leiden carriers.
    Morange PE; Aillaud MF; Nicaud V; Henry M; Juhan-Vague I
    Thromb Haemost; 2001 Dec; 86(6):1583-4. PubMed ID: 11776333
    [No Abstract]   [Full Text] [Related]  

  • 13. Thrombophilic mutations in Iran.
    Zeinali S; Duca F; Zarbakhsh B; Tagliabue L; Mannucci PM
    Thromb Haemost; 2000 Feb; 83(2):351-2. PubMed ID: 10739401
    [No Abstract]   [Full Text] [Related]  

  • 14. Factor V Leiden, protein C, and lipoprotein (a) in catheter-related thrombosis in childhood: a prospective study.
    Nowak-Göttl U; Dübbers A; Kececioglu D; Koch HG; Kotthoff S; Runde J; Vielhaber H
    J Pediatr; 1997 Oct; 131(4):608-12. PubMed ID: 9386668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study of the Leiden mutation (factor VQ 506), the most frequent cause of thrombophilia, in 116 thrombosis patients].
    Nagy A; Melegh B; Losonczy H
    Orv Hetil; 1997 Nov; 138(44):2797-800. PubMed ID: 9411348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of Arg306 mutations of factor V gene.
    Liang R; Lee CK; Wat MS; Kwong YL; Lam CK; Liu HW
    Blood; 1998 Oct; 92(7):2599-600. PubMed ID: 9746807
    [No Abstract]   [Full Text] [Related]  

  • 17. Co-segregation of thrombosis with the factor V Q506 mutation in an extended family with resistance to activated protein C.
    Beufé S; Borg JY; Vasse M; Charbonnier F; Moreau V; Monconduit M; Frebourg T
    Br J Haematol; 1995 Mar; 89(3):659-62. PubMed ID: 7734374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inherited resistance to activated protein C, a major cause of venous thrombosis, is due to a mutation in the factor V gene.
    Dahlbäck B
    Haemostasis; 1994; 24(2):139-51. PubMed ID: 7959362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In the presence of other inherited or acquired high-risk situations, the FV Cambridge mutation may be an additional thrombophilic risk factor, through its effect on APC sensitivity.
    Santacroce R; Bossone A; Brancaccio V; Fortina P; Margaglione M
    Thromb Haemost; 2000 Jun; 83(6):963-4. PubMed ID: 10896257
    [No Abstract]   [Full Text] [Related]  

  • 20. [Activated protein C resistance--a recently discovered hereditary thrombophilia].
    Moland L; Sandset PM
    Tidsskr Nor Laegeforen; 1998 Sep; 118(23):3590-5. PubMed ID: 9820002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.